Effects of Whole-Body Vibration Exercise on Serum IGF-1 in Fibromyalgia

This study has been completed.
Sponsor:
Information provided by:
Institut Nacional d'Educacio Fisica de Catalunya
ClinicalTrials.gov Identifier:
NCT00650715
First received: March 31, 2008
Last updated: NA
Last verified: March 2008
History: No changes posted

March 31, 2008
March 31, 2008
December 2004
January 2005   (final data collection date for primary outcome measure)
Serum IGF-1 levels [ Time Frame: Baseline, Week 1, Week 3, Week 6 ] [ Designated as safety issue: Yes ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Effects of Whole-Body Vibration Exercise on Serum IGF-1 in Fibromyalgia
Effect of Acute and Chronic Whole-Body Vibration Exercise on Serum Insulin-Like Growth Factor-1 Levels in Women With Fibromyalgia

The purpose of this study was to investigate the acute and chronic effect of whole-body vibration exercise on serum insulin-like growth factor-1 levels in women with fibromyalgia (FM). It was hypothesized that women with FM would exhibit an increase in IGF-1 following both acute and chronic WBV. Twenty-four women with FM were randomized into two groups: Vibration Group (VG) and Control Group (CG). The VG underwent a protocol with WBV exercise twice a week for a total of six weeks, whereas the CG performed the same protocol without vibratory stimulus. Both groups continued with their usual pharmacological treatment. Serum IGF-1 levels were determined using Enzyme-Linked Immunosorbent Assay (ELISA). To test the effect of chronic WBV, serum IGF-1 measurements were taken at baseline and at weeks 1,3, and 6 of intervention. To test the effect of acute WBV, within week 1, serum IGF-1 measurements were taken before and immediately following a session of WBV.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
  • Fibromyalgia
  • Hormonal Responses to Exercise in Patients With Fibromyalgia.
  • Device: Vibratory platform, PowerPlate®, Badhoevendorp, Netherlands
    Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. The Whole-body vibration intensity was kept constant at 30 Hz of frequency and 2 mm of amplitude.
  • Device: Placebo Whole-body vibration exercise
    Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. All exercises were performed without the influence of a vibratory stimulus.
  • Active Comparator: VG
    Vibration Group (VG) underwent a protocol with whole-body vibration exercise twice a week for a total of six weeks. The group continued with their usual pharmacological treatment.
    Intervention: Device: Vibratory platform, PowerPlate®, Badhoevendorp, Netherlands
  • Placebo Comparator: CG
    The Control Group (CG) underwent the same protocol of exercises than VG but without vibratory stimulus. The CG continued with their usual pharmacological treatment.
    Intervention: Device: Placebo Whole-body vibration exercise
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
January 2005
January 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients diagnosed of fibromyalgia according to the American College of Rheumatology criteria for at least three years.

Exclusion Criteria:

  • Orthopedic limitation, or cardiovascular, pulmonary, or metabolic disease that would preclude exercise.
  • Participation in any other study.
Female
35 Years to 69 Years
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT00650715
WBVIGF1FM
Not Provided
Eduard Alentorn-Geli, MD, INEFC
Institut Nacional d'Educacio Fisica de Catalunya
Not Provided
Principal Investigator: Eduard Alentorn-Geli, MD INEFC
Institut Nacional d'Educacio Fisica de Catalunya
March 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP